GlassScriptPhysician profile
Tasleem Katchi
NPI 1114303617
$8,302.59
in general payments reported to CMS, 2019-2025
22 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2021: $1,649 · 2022: $4,641 · 2023: $459 · 2024: $729 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,725.60 | 2021-2022 | |
| Edwards Lifesciences Corporation | $1,660.74 | 2019-2021 | |
| Abbott Laboratories | $1,626.63 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $438.63 | 2022-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $315.06 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $203.43 | 2022-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $183.99 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $161.00 | 2019-2025 | Brilinta, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.88 | 2023-2025 | Jardiance |
| Pfizer INC. | $131.93 | 2024 | |
| Abiomed | $123.90 | 2022 | |
| Cardiovascular Systems INC. | $120.20 | 2022 | |
| Akcea Therapeutics, INC. | $118.73 | 2019 | |
| Boston Scientific Corporation | $92.40 | 2021 | |
| Merck Sharp & Dohme LLC | $66.80 | 2023 | Verquvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $37.66 | 2023 | Glidewire, Metacross Otw, Tr Band |
| Bayer Healthcare Pharmaceuticals INC. | $36.55 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $24.31 | 2024 | |
| Genzyme Corporation | $23.86 | 2023 | |
| Alnylam Pharmaceuticals INC. | $19.89 | 2025 | Onpattro |
| Esperion Therapeutics, INC. | $17.24 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $17.16 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tasleem Katchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.